HIV peripheral neuropathy progression: protection with glucose-lowering drugs?

TitleHIV peripheral neuropathy progression: protection with glucose-lowering drugs?
Publication TypeJournal Article
Year of Publication2012
AuthorsEvans SR, Lee AJ, Ellis RJ, Chen H, Wu K, Bosch RJ, Clifford DB
JournalJ Neurovirol
Volume18
Issue5
Pagination428-33
Date Published2012 Oct
ISSN1538-2443
KeywordsAdolescent, Adult, Anti-HIV Agents, Asymptomatic Diseases, Blood Glucose, Child, Disease Progression, Drug Therapy, Combination, Female, HIV Infections, HIV-1, Humans, Hypoglycemic Agents, Male, Middle Aged, Odds Ratio, Peripheral Nervous System Diseases, Risk Factors
Abstract

The purpose of this study is to evaluate risk factors for progression from asymptomatic peripheral neuropathy (APN) to symptomatic peripheral neuropathy (SPN). Antiretroviral therapy (ART)-naïve patients initiating combination ART were followed longitudinally and screened for signs/symptoms of PN. Having APN was associated with higher odds of future SPN (odds ratio (OR) = 1.58, 95 % confidence interval (CI) = (1.08, 2.29), p = 0.027). Neurotoxic ART use was associated with increased odds of progression to SPN (OR = 2.16, 95 % CI = (1.21, 3.85), p = 0.009) while use of glucose-lowering drugs (non-insulin) was protective (OR = 0.12, 95 % CI = (0.02, 0.83), p = 0.031). Use of glucose-lowering drugs (non-insulin) may prevent progression from APN to SPN.

DOI10.1007/s13365-012-0119-9
Alternate JournalJ. Neurovirol.
PubMed ID22806348
PubMed Central IDPMC3485691
Grant List1 U01 068634 / / PHS HHS / United States
AI068636 / AI / NIAID NIH HHS / United States
NS32228 / NS / NINDS NIH HHS / United States
P30 MH062512 / MH / NIMH NIH HHS / United States
R01 NS032228 / NS / NINDS NIH HHS / United States